Biotech leader Gilead Sciences saw its stock spike nearly 6% after delivering favorable Q4 results, with sales of $7.92 billion and net income of $2.2 billion. The stock has soared over 100% in the last two years, hitting an all-time high of $157 a share.

Gilead’s post-earnings rally was fueled by FY25 EPS spiking 76% to $8.15 and annual sales increasing over 2% to $29.44 billion. Despite slightly lower than expected FY26 guidance, Gilead’s EPS guidance of $8.45-$8.85 surpassed analyst estimates.

Trading at 17X forward earnings, Gilead offers a 2.15% dividend yield and boasts an ROIC of 24%, outperforming industry peers. The stock presents an intriguing option for long-term investors seeking value and income, with potential for higher highs depending on FY26 EPS revisions.

Read more at Nasdaq: Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?